Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
Ishiguro
H
H
Kitano
T
T
Yoshibayashi
H
H
Toi
M
M
Ueno
T
T
Yasuda
H
H
Yanagihara
K
K
Garbo
C L
CL
Fukushima
M
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001835:Body Weight; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007564:Japan / Q000208:ethnology; D008408:Mastectomy; D020360:Neoadjuvant Therapy; D009503:Neutropenia / Q000139:chemically induced*; D017239:Paclitaxel / Q000008:administration & dosage; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage
D011994:Recombinant Proteins; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D000069585:Filgrastim